{"id":"nimustine","rwe":[{"pmid":"41890358","year":"2026","title":"Long-term outcome of nimustine-based chemotherapy for oligodendroglioma.","finding":"","journal":"Neuro-oncology advances","studyType":"Clinical Study"},{"pmid":"41557247","year":"2026","title":"Induction chemotherapy with methotrexate, nimustine, and procarbazine for primary CNS lymphoma in the elderly: a retrospective evaluation of safety and efficacy.","finding":"","journal":"Journal of neuro-oncology","studyType":"Clinical Study"},{"pmid":"40528440","year":"2025","title":"Effects and safety of TMZ plus RT combined with other drugs in the treatment of glioblastoma: a network meta-analysis.","finding":"","journal":"Future oncology (London, England)","studyType":"Clinical Study"},{"pmid":"40439586","year":"2025","title":"Quantifying Nitrosoureas: Comprehensive Insights into Analytical Techniques Transforming Cancer Research.","finding":"","journal":"Critical reviews in analytical chemistry","studyType":"Clinical Study"},{"pmid":"40421419","year":"2025","title":"Bioinformatics and experimental validation of ferroptosis-related genes in steroid-induced osteonecrosis of the femoral head.","finding":"","journal":"Frontiers in molecular biosciences","studyType":"Clinical Study"}],"tags":[{"label":"nimustine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01AD06","category":"atc"},{"label":"Active","category":"status"},{"label":"Antineoplastic Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["nimustine","nimustine hydrochloride","nimustine HCl"],"offLabel":[],"synonyms":["nimustine","nimustine hydrochloride","nimustine HCl"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"nimustine","explanation":"Imagine your DNA as a long, twisted ladder. Nimustine disrupts this ladder by forming strong chemical bonds between the rungs, making it difficult for the cell to repair the damage. This ultimately leads to cell death, which is beneficial in the context of cancer treatment.","oneSentence":"Nimustine works by inducing DNA damage through the formation of cross-links and strand breaks.","technicalDetail":"Nimustine exerts its cytotoxic effects through the alkylation of DNA, resulting in the formation of DNA-protein cross-links and single-strand breaks, which trigger cell cycle arrest and apoptosis."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3384","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NIMUSTINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NIMUSTINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:58:28.821169","biosimilars":[],"competitors":[{"drugName":"carmustine","drugSlug":"carmustine","fdaApproval":"1977-03-07","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"lomustine","drugSlug":"lomustine","fdaApproval":"1976-08-04","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"streptozocin","drugSlug":"streptozocin","fdaApproval":"1982-05-07","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"uracil mustard","drugSlug":"uracil-mustard","fdaApproval":"1962-09-13","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"nimustine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"carmustine","brandName":"carmustine","genericName":"carmustine","approvalYear":"1977","relationship":"same-class"},{"drugId":"lomustine","brandName":"lomustine","genericName":"lomustine","approvalYear":"1976","relationship":"same-class"},{"drugId":"streptozocin","brandName":"streptozocin","genericName":"streptozocin","approvalYear":"1982","relationship":"same-class"},{"drugId":"uracil-mustard","brandName":"uracil mustard","genericName":"uracil mustard","approvalYear":"1962","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02698280","phase":"PHASE2","title":"Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2015-07","conditions":["Glioblastoma"],"enrollment":23,"completionDate":"2018-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"006595","UNII":"0S726V972K","CHEBI":"CHEBI:75270","INN_ID":"4258","UMLSCUI":"C0028096","ChEMBL_ID":"CHEMBL136737","KEGG_DRUG":"D01059","DRUGBANK_ID":"DB13069","PUBCHEM_CID":"39214","SECONDARY_CAS_RN":"55661-38-6","MESH_DESCRIPTOR_UI":"D015376"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":344,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01AD06","allCodes":["L01AD06"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan-Dec","pmid":"41890358","title":"Long-term outcome of nimustine-based chemotherapy for oligodendroglioma.","journal":"Neuro-oncology advances"},{"date":"2026 Jan 20","pmid":"41557247","title":"Induction chemotherapy with methotrexate, nimustine, and procarbazine for primary CNS lymphoma in the elderly: a retrospective evaluation of safety and efficacy.","journal":"Journal of neuro-oncology"},{"date":"2025 Jul","pmid":"40528440","title":"Effects and safety of TMZ plus RT combined with other drugs in the treatment of glioblastoma: a network meta-analysis.","journal":"Future oncology (London, England)"},{"date":"2025 May 29","pmid":"40439586","title":"Quantifying Nitrosoureas: Comprehensive Insights into Analytical Techniques Transforming Cancer Research.","journal":"Critical reviews in analytical chemistry"},{"date":"2025","pmid":"40421419","title":"Bioinformatics and experimental validation of ferroptosis-related genes in steroid-induced osteonecrosis of the femoral head.","journal":"Frontiers in molecular biosciences"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"NIMUSTINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nimustine is a small molecule that acts as a DNA disrupting agent. It has been studied in combination with bevacizumab for the treatment of recurrent high-grade glioma, a type of brain cancer.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}